Clinical Trial: An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593391) titled 'An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome' on March 24.

Brief Summary: This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phelan- McDermid Syndrome.

Study Start Date: May 06

Study Type: INTERVENTIONAL

Condition: Phelan-McDermid Syndrome

Intervention: DRUG: NNZ-2591

The study drug will be administered twice daily orally.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Neuren Pharmaceuticals Limited

Published by HT Digital Content Services with permission from Health Daily Diges...